Market Reflection

Report
March 2015

Month Growth %

IPM overview
25

25

20

2015

15

2014

10

2013

5
0

20
15
10
5
0

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Jan

Feb

Mar

Apr

TSA IPM Trends

May

Jun

Jul

Aug

+13%
MAT

90,346

Month

76,482

Value Rs. crs

80,566

67,709

73,096

Growth
SPLY

66,054

2012

2013

6,414
2014

Nov

+16%

+12%

5,861

Oct

SSA IPM Trends

+16%

5,446

Sep

7,464

2015

61,394
55,577

4,551
2012

4,884
2013

5,395
2014

6,281

2015

IPM was valued at Rs. 90,346 crs and the retail sector was valued at Rs. 76,482 crs as of MAT Mar15 with CAGR growth of 11%
during the period 2012-15
Anti-infectives, Cardiac and Gastro Intestinal remains the leading therapeutic categories accounting for 36% of IPM
Indian companies continue to drive growth in the market with Sun catapulted to the top of the league, after its merger deal with
Ranbaxy fructified, as forecasted by IMS Health in Jan 15
Acute therapies dominates the market constituting 70% of IPM
1

Market Reflection Report March 2015

Dec

Top 150 companies snapshot

IPM value Rs.7,464 crs (16% Growth)
Month Mar 15
Value (Rs. Crs)

381

Rank #41 - 60

488

Rank #61 - 100

494

249

15

18

14

18

14

% MS

12

21

19,244

13

11

9,976

4,762

5,901

6,029

3,087

% Gwth

43

38,851

21

11

830

Rank #31 - 40

Rank #101 - 150

Value (Rs. Crs)

22

1,623

Rank #11 - 20

% Gwth

43

3,193

Rank #1 - 10

Rank #21 - 30

% MS

IPM value Rs.90,346 crs (12% Growth)

MAT Mar 15

11

12

18

12

Lupin moved up among the top 10 companies as a result of the merger of Ranbaxy with Sun; the market share of
the top 10 companies increased from 40% of IPM in Feb 15 to 43% in Mar 15 on MAT and month basis
The top 150 companies continue to account for 97% of IPM on MAT and month basis
Source: IMS Health TSA, Mar 15

Market Reflection Report March 2015

Top companies #1-10

Sun

Month

Cipla

470
269

Zydus Cadila

261

GlaxoSmithKline

254

Alkem

250

Macleods Pharma

248

19

226

Lupin Limited

214

24
7
10
19
26
11
17

Value
(Rs. Crs)
Sun

Cipla

MAT

Zydus Cadila

3,171

Alkem

3,113

GlaxoSmithKline

3,088

Macleods Pharma

2,933

Pfizer

2,745

Lupin Limited

220
218

3.4

Zydus Cadila
Macleods Pharma

217

3.3

GlaxoSmithKline

204

3.0

Lupin Limited

181

Intas Pharma

179

8.3
6.4
20

3
19
11
5

2,581

5.3
3.5

23
9
15

18

11

2.9
32

% Gwth

Alkem

2,717

Zydus Cadila

2,667

% MS

8.4

6.5
16

3,777

3.5

2.8

11

6,398

3.5

3.5
3.3

18

4,974

4.9

20
12

3.7
3.6

3.5

3.4

Macleods Pharma

2,556

3.3

GlaxoSmithKline

2,523

3.0

Pfizer

2,218

2,173

3.5
27

2,825

Lupin Limited

3.5

Mankind

2.9

3.8

21

Sun
Abbott

4.8

24

Value
(Rs. Crs)

Cipla

8.3
6.4

240

3.4

4,760

Mankind

Alkem

10

7,538

3,181

3.5

% MS

12

401

3.6

% MS

11

302

Mankind

2.9

% Gwth

5,742

Cipla

5.1

% Gwth

524

Abbott

6.3

TSA

Pfizer

Sun

8.3

12

382

Mankind

Abbott

11

618

Abbott

Value
(Rs. Crs)

% MS

% Gwth

SSA

Value
(Rs. Crs)

25

3.3
3.3
2.9

16

2.8

TSA: Macleods registered significant growth greater than 20% both on MAT and month basis.
SSA: Intas registered double the growth % of IPM during the month while Macleods and Mankind registered
significant growth greater than 20% both on MAT and month basis
Source: IMS Health TSA & SSA, Mar 15
3

Market Reflection Report March 2015

Top companies #11-20

% Gwth

Month

Intas Pharma

182

Aristo Pharma

176

Dr Reddys Labs

175

Emcure

169

Sanofi
USV

Glenmark Pharma

28
8
16

122

Torrent Pharma

2,170

11

Emcure

2,126

12

2,061

Dr Reddys Labs
Glenmark Pharma
USV

15
13

1,949

1,746

1,517

Alembic

1,494

Dr Reddys Labs

146

Emcure

144

% MS

2.6

14

135
128

Sanofi

123

Alembic

113

Micro Labs

104

1,902

Emcure

2.0

2.5

30

2.3

2.3
15

2.2

19

2.0
2.0
1.7

% MS

21

1,577
1,551

Alembic

1,354

1.7

Micro Labs

1,284

2.4

13

2.3

17
10
11
15
9

2.2
2.1

19

1,544

1.7

2.7
2.5

16

1,777

USV

1.8

12

1,651

Glenmark Pharma
Sanofi

2.6

28

2,037

1,796

Dr Reddys Labs

25

% Gwth

Aristo Pharma

2.3

2.8

15

Torrent Pharma

2.2

24

Value
(Rs. Crs)
Intas Pharma

% MS

10

2.4

1.9

USV
Glenmark Pharma

2.4

2.2
19

1,781

Micro Labs

2.4
2.3

21

2,381

2,019

156

1.6

% Gwth

Sanofi

160

Aristo Pharma

1.7

12

Aristo Pharma

Torrent Pharma

TSA

Micro Labs

2.4

2.0

24

177

2.4

2.0

20

% Gwth

Pfizer

2.2

14

147

Value
(Rs. Crs)

MAT

28

167

125

2.8

24

149

Alembic

Intas Pharma

33

209

Torrent Pharma

Value
(Rs. Crs)

% MS

SSA

Value
(Rs. Crs)

2.0
2.0
1.8
1.7

TSA The majority of companies in this bucket posted significant growth greater 20% than during the month
SSA Similarly, Dr. Reddys, Aristo, Torrent and Alembic posted strong retail growth greater than 20% during the
month
Source: IMS Health TSA & SSA, Mar 15
4

Market Reflection Report March 2015

Top companies #21-30

% Gwth

Month

Wockhardt Ltd
Ipca Labs

109
106

FDC
Unichem

79

MSD Pharma

78

6
15

70

Merck Limited

61

Franco Indian

61

Indoco

55

20

Ipca Labs

1,303
1,284

FDC

16

1.3

12

72

1.1

1.0

60

0.8

Franco Indian

57

11

0.9

0.8

Merck Limited

54

11

0.9

1.5
20
14

Indoco

1,164

Ipca Labs

1,139

1.4

Wockhardt Ltd

1,101

1.2

FDC

1.1

Unichem

959

1.1

0.8

% Gwth

Novartis Intl.

0.9

21

49

1.4

1,060

0.9

25

Value
(Rs. Crs)

1,006

15

1.5
1.5

58

% MS

850

35
6

MSD Pharma

FDC

MSD Pharma

1.6

Cadila Pharma

Unichem

Cadila Pharma

27

84

Unichem

0.7

% Gwth

Wockhardt Ltd

96
93

0.9

12

1,336

Ipca Labs
Novartis Intl.

1.0
28

Novartis Intl.

1.5

1.1

% MS

99

1.4
1.2

11

% Gwth

Wockhardt Ltd

TSA

Cadila Pharma

1.6

32

91

Value
(Rs. Crs)

MAT

37

121

Novartis Intl.

Value
(Rs. Crs)

% MS

SSA

Value
(Rs. Crs)

982

MSD Pharma

757
724

1.5
22

1.5

10

1.4

1.3

913

Cadila Pharma

% MS

1.2

1.0
15

1.0

Merck Limited

777

0.9

Franco Indian

689

10

0.9

Franco Indian

733

10

0.8

Merck Limited

686

10

0.9

Indoco

668

0.7

Indoco

11

12

604

0.8

TSA Wockhardt and Ipca registered double the IPM growth during the month
SSA Wockhardt, Ipca, Indoco and Cadila registered significant growth of 20% during the month
Source: IMS Health TSA & SSA, Mar 15

Highlights
TSA

SSA

Movers & Shakers TSA: Companies

Movers & Shakers SSA: Companies

In the month of March15(in comparison to

Feb15), among the top 25 companies

In the month of March-15 (in comparison to

February-15 month), among the TOP 25
companies

Sun Pharma has moved 2 ranks to achieve top

position in the IPM with market share of 8.28 %.
Aristo Pharma has gained 4 ranks and moved to
13th position.
Glaxosmithkline has gained 3 ranks and moved
to 6th position.
Dr Reddys Labs & USV have gained 2 ranks
and moved to 14th & 17th position respectively.
As per March15 MAT (in comparison to
Feb15) among the top 25 companies

Sun Pharma has moved 2 ranks to achieve top

position in the IPM with market share of 8.34 %.
Alkem & Lupin have gained 3 ranks each &
occupied 5th & 9th position respectively.
Dr Reddys Labs & USV have gained 2 ranks
each & occupied 14th & 16th position
respectively.
Intas gained 1 rank to occupy the 10th position

Sun Pharma has moved 2 ranks to achieve top

position in the IPM with market share of 8.34 %.

As per March-15 MAT (in comparison to

February-15 MAT), among the TOP 25
companies

Companies below Ranbaxy have gained 1 rank

post Sun-Ranbaxy merger.

Sun Pharma has moved 2 ranks to achieve top

position in the IPM with market share of 8.36 %.
Aristo Pharma & Glenmark have gained 2 ranks
each & occupied 13th & 17th position
respectively.

Market Reflection Report March 2015

NLEM/Non-NLEM
Value

SPLY
Feb '15

Mar '15

Rs. (crs)

Value Growth
(%)

Rs. (crs)

Rs. (crs)

989.1

1091.9

10.4

1119.2

1091.9

-2.4

Non-NLEM

5424.5

6371.7

17.5

6439.7

6371.7

-1.1

IPM

6413.6

7463.6

16.4

7558.8

7463.6

-1.3

NLEM

Mar '14

Mar '15

Rs. (crs)

Previous month
Value Growth (%)

SPLY

Volume

Mar '14

Previous month

Mar '15

Feb '15

Units (000)

Units (000)

Volume Growth
(% )

Mar '15

Units (000)

Units (000)

Volume Growth
(%)

380800

399972

5.0

406526

399972

-1.6

Non-NLEM

1184052

1298946

9.7

1322253

1298946

-1.8

IPM

1564851

1698918

8.6

1728779

1698918

-1.7

NLEM

NLEM impacted drugs constituted 15% of IPM in value terms with a growth of 10.4% as of MAT Mar 15 over same
period last year (SPLY)
The share of the non-NLEM drugs was 76% of IPM in volume terms for the month of Mar15
Source: IMS Health TSA, Mar 15

Market Reflection Report March 2015

Indian /MNC trends

% Gwth over same month last year

Month Growth

25
20

Indian
IPM

15

MNC

10
5
0
Apr 14

May 14

Jun 14

Jul 14

Aug 14

Sep 14

Oct 14

Nov 14

Dec 14

Jan 15

Feb 15

Mar 15

Value (Rs. Crs)

8,000

IPM

Value

7,000
6,000

Indian

5,000
4,000
3,000
2,000

MNC

1,000
0
Apr 14

May 14

Jun 14

Jul 14

Aug 14

Sep 14

Oct 14

Nov 14

Dec 14

Jan 15

Feb 15

Mar 15

Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of
18.6% over Mar14
MNCs registered a growth of 10.4% as against the IPM growth of 16.4% during the month
Source: IMS Health TSA, Mar 15

Market Reflection Report March 2015

Acute/Chronic trends
Growth (%)

25

IPM

Acute

Chronic

20
15
10
5

Top 5 TC 4s

Apr 14

May 14

Aug 14

Sep 14

20.40

Oct 14

Nov 14

Dec 14

17.63

Jan 15

-5.05

Feb 15

Mar 15

23.03

155

Cough Preps Ethical

Value (Rs. Crs)

Top 3 Cos. in TC4

Jul 14

30.37

Growth (%)
Value (Rs.
Crs)

Jun 14

16

Wockhardt Ltd

Franco Indian

108

DPP4 inhibitors & Comb

Glim+Metformin

Value (Rs. Crs)

19

Glenmark Pharma

118

Value (Rs. Crs)

MSD Pharma

27

USV

Novartis Intl.

26

Sun

Lupin Limited

USV

19

23

88

87

Food Supplements

Amoxy. & Clav. Solids

Value (Rs. Crs)

Value (Rs. Crs)

Apex

15

GlaxoSmithKline

17

11

Abbott

14

Mankind

14

10

Nutricia Internat

13

Alkem

14

Acute therapies continue to dominate the market accounting for 70% of the market during the month
Chronic therapies registered growth of 15%, while acute therapies posted growth of 17% in Mar 15
Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 30% during the
month
Source: IMS Health TSA, Mar 15
9

Market Reflection Report March 2015

Top 40 brands
% Gwth

Augmentin (GlaxoSmithKline)

Top 1-10

Corex (Pfizer)

0.51

21

28

16

26

Liv-52 (Himalaya Drug)

16

Shelcal (Torrent Pharma)

16

Foracort (Cipla)

16

Zifi (FDC)

15

23

38

0.31

23

36

0.31

23

Thyronorm (Abbott)

22

Clavam (Alkem)

21

Phensedyl Cough (Abbott)

20

Voveran (Novartis Intl.)

20

18
25
8
29

% Gwth

20

Dexorange (Franco Indian)

19

Spasmo-Proxyvon + (Wockhardt)

19

Volini (Sun)

0.30

47

Panderm+ (Macleods Pharma)

19

Novomix (Abbott)

19

Synflorix (GlaxoSmithKline)

18

Galvus Met (Novartis Intl.)

18

0.29

37

0.22

40

0.21

20

0.21

37

0.21

15

13

0.20

Zincovit (Apex)

15

11

0.20

0.28

Calpol (GlaxoSmithKline)

15

27

0.20

Moxikind-CV (Mankind)

15

28

0.20

0.26

Pan (Alkem)

14
Value
(Rs. Crs)

Electral (FDC)
Duphaston (Abbott)

14

Taxim-O (Alkem)

14

0.24
0.24

0.19

Budecort (Cipla)

14

Azithral (Alembic)

13

Eltroxin (GlaxoSmithKline)

13

Zinetac (GlaxoSmithKline)

13

% MS

18

14

0.26
0.26

17

% Gwth

0.26

0.25

83
17

0.27

0.26

18

0.22

Becosules (Pfizer)

% MS

45

% MS

26

17

0.38

Prevenar-13 (Pfizer)

Glycomet-GP (U S V)

Alburel (Reliance Lifescie.)

% Gwth

0.35

Monocef (Aristo Pharma)

Value
(Rs. Crs)

Top 11-20

11

38

Top 21-30

Mixtard (Abbott)

Value
(Rs. Crs)

% MS

Top 31-40

Value
(Rs. Crs)

0.19

13

0.19

18

0.19

38
30
10

0.17

0.17

Lantus (Sanofi)

18

0.24

Taxim (Alkem)

13

14

0.17

Betadine (Win Medicare)

18

0.24

Aciloc (Cadila Pharma)

13

13

0.17

Janumet (MSD Pharma)

17

0.23

Pan-D (Alkem)

12

20

25

Abbott, Alkem and GlaxoSmithKline have the highest number of brands among the top 40 at 5 each
The vaccine Synflorix (GlaxoSmithKline) registered outstanding growth of 83% during the month
Thyronorm (Abbott), Spasmo-Proxyvon + (Wockhardt) and Shelcal (Torrent Pharma) posted impressive growth
greater than 40% in Mar 15 over the same month last year
Source: IMS Health TSA, Mar 15
10

0.19
0.18

Market Reflection Report March 2015

0.16

Star Brands of the month

TSA
Movers & Shakers TSA: Products
Among the Top 25 Products as per Mar15 MAT (in comparison to Feb15 MAT)
Mixtard is the No 1 brand.
Thyronorm and Voveran has gained 2 ranks each to occupy 6th and 14th position respectively.
Aciloc has gained 4 ranks to occupy 25th position.
Shelcal has gained 1 rank to occupy 23rd position.
Among the Top 25 products as per March15 month (in comparison to Feb15 month)
Mixtard is the No 1 brand.
Synflorix has gained 24 ranks to occupy 16th position.
Spasmo-Proxyvon + has gained 6 ranks to occupy 13th position.
Dexorange and Zifi have gained 5 ranks each to occupy 12th and 25th position respectively.
Prevenar-13, Monocef & Alburel have gained 4 ranks each to occupy 4th, 5th and 21st position respectively.

Shelcal has gained 3 ranks each to occupy 23rd position.

Volini has gained 2 ranks to occupy 11th position.
Phensedyl Cough & Voveran have gained 1 rank each to occupy 9th & 10th position respectively.

11

Market Reflection Report March 2015

Therapy trends
Value (Rs Crs)

MS %
7,464

IPM

Cardiac

14
12

866

Gastro Intestinal

Pain / Analgesics

591

Anti Diabetic

589

Vitamins / Minerals / Nutrients

535

Derma

456

Neuro / CNS

450

Gynaec.

416

Others

Vaccines

240

178

3
2

-4

13

-1

17

630

-1

20

10

774

Respiratory

16

100

1,066

Anti-infectives

Gwth% (Prev. Mth)

Gwth % (SPLY)

21

-9

15

-1

18

11

17

-2

15

-1

11

22

36

Vaccines continues to record remarkable value growth of 36% as of MAT Mar 15

Anti-infectives constitute the largest market share of 14%, with significant growth on MAT basis
Source: IMS Health TSA, Mar 15

12

Market Reflection Report March 2015

Top Therapy Trends

Value
(Rs. Crs)
Amoxy. & Clav. Solids

16

54
48

Azithromycin Oral Solids

44

Cefpodoxime Solids

42

Piperacillin+Tazobactam

33

Meropenem

33

Cefuroxime Oral Solids

30

Amikacin

29

39
27
30
22
7
16

Rabepra.+ Domperid.

43

27

GI

33

Atenolol+Amlodipine

32

Telmisartan + Hct

31

Enoxaparin

29

Amlodipine

29

Codeine And Comb.

38

15
47
23
20

Cold Prep. Liquids

22
12
15
11
6
9
26

24

18

% Gwth (SPLY)

35

176
67
42

Levocetiriz.+Montelu Sold

40

Formoteral+Budesonide

31

Cold Prep. Solids

30

Salmeterol+Fluticasone

21

Omepraz.+ Domperid.

23

14

Budesonide

18

Rabeprazole

22

13

Salbutamol+Ipratropium

15

Digest. Inc. Enzyme Liqui

21

Levocetirizine

14

26

14
23

Value
(Rs. Crs)

24
14

29

24

Metoprolol

Cough Prep. Ethicals

39

Ranitidine Oral Solids

Others

40

25

47

Antacid+Antiflatu.Liq

Telmisartan

% Gwth (SPLY)

Pantopr.+ Domperid.

Pantoprazole Solids

43

Losartan+ Hydrochlorthiaz

% Gwth (SPLY)

66

Rosuvastatin

Amlodipine+Telmisartan

28

Value
(Rs. Crs)

Oral Electrolytes

Cardiac

Amoxy. & Clav. Liquids

Respiratory

Anti-Infective

30

57

Cefixime Oral Sol.

Atorvastatin

28

95

Ceftriaxone Injectabls

Value
(Rs. Crs)

% Gwth (SPLY)

8
23
26
23
24
17
42
28
21

Oral Electrolytes, Budesonide, Amoxy. & Clav. Liquids and Cough Prep. Ethicals registered significant growth greater
than 34% over the same period last year
Source: IMS Health TSA, Mar 15

13

Market Reflection Report March 2015

Glossary
Abbreviation

14

Description/Definition

IPM

Indian Pharmaceutical Market

MAT

Moving Annual Total

CAGR

Compound Annual Growth Rate

TSA

Total Sales Audit

SSA

Secondary Sales Audit

Gwth

Growth

MS

Market Share

Rs

Rupees

NLEM

National List of Essential Medicines

SPLY

Same Period Late Year

MNC

Multi-National Company

DPP

Dipeptidyl Peptidase 4

TC

Therapeutic Category

Crore / crs

10 million

Market Reflection Report March 2015

About IMS Health

Worlds leading provider of healthcare consulting, technology, and informatics

Founded in 1954

95 process patents
worldwide in life sciences processes

Operates in over 100 countries; employs 10,000+ people

world wide

Ranked 2nd Life Science

Data from 100,000 suppliers and insights of more than 40

billion healthcare transactions

Technology Vendors for 2013 (IT

Services) by IDC

1200+ experts resources, 3000+ service resources and

5000+ clients

Worlds most admired

companies FORTUNE Magazine

Operational in India f or more than 11 years, with over 2000

employees with of f ices in Gurgaon, Mumbai, Delhi &
Bangalore

2008 and 2010

OUR SERVICE OFFERINGS

PHARMA
LIFE-SCIENCES
PHARMAAND
& ALLIED
HEALTH

PUBLIC HEALTH

PAYERS

PROVIDERS

Product & Portfolio strategy

Entry & Growth Strategy
Brand and Commercial Strategy
Pricing and market access
Launch and commercial Excellence
Performance management
Transaction Advisory Services and
Due Diligence
Drug sales database (global and local)
Census - Physicians, Chemists,
Hospitals, Doctor , etc

Policy reforms and advocacy

Enabling evidence based public health
decisions
Health infrastructure development
Health resources planning and
allocation
Monitoring & evaluation
Designing and implementation support
Strengthening health care supply
chain
Enabling Technology Solutions

Network expansion and management

Doctor selection
Pharma & Provider engagement
strategy
Disease management
Claims database
Claims analytics benchmarks and
costs
Patient level information
Health technology assessment

Provider databases
Hospital performance transformation
programs
Performance benchmarking
Expansion & Growth strategy
Feasibility analysis and business plan
development
Brownfield hospital acquisition
Financial modeling, funding modalities
and transaction advisory
BI Solutions for hospitals

15

Disclaimer

16

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats,
and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the
completeness or accuracy of such third party sources or data.

IMS Health captures 90% of the retail sector and 65% of the hospital sector through individual audits, the Stockist Sell-Out Audit (SSA) and Hospital
Secondary Audit (HSA), as well as the dispensing doctors sector as part of the Total Sales Audit (TSA) from 2007 onwards. The combined audited
sectors accounted for an estimated 87.4% of the total pharmaceutical market in 2014.

As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks
and uncertainties, and are not to be considered guarantees of any particular outcome.

It should neither be regarded as comprehensive nor sufficient for making decisions, nor should it be used in place of professional advice. IMS Health
accepts no responsibility for any loss arising from any action taken or not taken by anyone using this material.

All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by
any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of
IMS HEALTH.

2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.